AZN - AstraZeneca PLC
| Previous Close | 37.80 |
| Open | 37.63 |
| Bid | 0.00 x 3200 |
| Ask | 37.68 x 800 |
| Day's Range | 37.58 - 37.91 |
| 52 Week Range | 34.38 - 43.30 |
| Volume | 1,716,339 |
| Avg. Volume | 5,424,290 |
| Market Cap | 100.517B |
| Beta (3Y Monthly) | 0.47 |
| PE Ratio (TTM) | 39.77 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.40 (3.72%) |
| Ex-Dividend Date | 2019-02-28 |
| 1y Target Est | N/A |
- Zacks•3 days ago
Rigel Initiates Enrollment in Pivotal Blood Disorder Study
Rigel (RIGL) enrolls first patient in a pivotal label expansion study evaluating its approved drug, Tavalisse, in patients with antibody autoimmune hemolytic anemia.
- Motley Fool•5 days ago
3 Top Diabetes Stocks to Watch in May
These three diabetes stocks should be on your radar right now.
- GuruFocus.com•6 days ago
AstraZeneca Needs New Breast Cancer Drug to be Blockbuster
AstraZeneca (ZN) needs a blockbuster to justify its nearly $7 billion investment for a share of Japan-based Daiichi Sankyo's (TSE:4568) drug to treat a type of breast cancer. Warning! GuruFocus has detected 5 Warning Signs with AZN. The HER2-targeting antibody drug conjugate (ADC) and potential new medicine was evaluated in patients with HER2-positive, unresectable and/or metastatic breast cancer previously treated with another drug combination.
- Zacks•9 days ago
AVEO Pharmaceuticals (AVEO) Q1 Earnings & Revenues Miss Mark
AVEO Pharmaceuticals (AVEO) discourages investors in Q1 with wider-than-expected loss as well as a revenue miss. Also, Fotivda NDA gets delayed as the FDA was dissatisfied with the OS data.
- Zacks•10 days ago
Inovio (INO) Q1 Earnings & Revenues Fall Short of Estimates
Inovio Pharmaceuticals' (INO) earnings and revenues disappoint with an estimate miss in the first quarter. Shares slip in after-hours trading.
- Zacks•10 days ago
Pharma Stock Roundup: AGN, NVO Report Q1 Earnings, NVS to Buy Takeda's Eye Drug
Allergan (AGN) and Novo Nordisk (NVO) announce Q1 results. Novartis buys rights to Takeda's dry eye disease drug, Xiidra.
- MarketWatch•11 days ago
Drugmakers’ lobbying spending at 10-year high as Washington targets soaring prices
The spending by the industry’s main trade group and seven key drugmakers has climbed to a level not seen in a decade.
Bloomberg•11 days agoAstraZeneca Gets an $8 Billion Punishment
AstraZeneca Plc’s first-ever stock sale has been a painful experience. The British drugmaker was exploiting its strong share price to get its financial house in order. Right now, its free cash flow isn’t enough to cover the dividend without some help from disposals.
- Zacks•12 days ago
Clovis (CLVS) Q1 Earnings Top Estimates, Rubraca Sales Strong
Clovis (CLVS) reports encouraging first-quarter 2019 results. Rubraca maintains market share during the quarter.
- Zacks•13 days ago
Guardant Health (GH) to Report Q1 Earnings: What's in Store?
At Guardant Health's (GH) Q1 conference, investors will watch out for the updates on liquid biopsy-based Guardant360 and GuardantOMNI tests that could help detect advanced stages of cancer.
- Zacks•17 days ago
Ironwood (IRWD) Q1 Earnings & Revenues Miss, Shares Fall
Ironwood (IRWD) misses on both earnings and sales in the first quarter. The company completes its separation into two entities.
- Thomson Reuters StreetEvents•18 days ago
Edited Transcript of AZN.L earnings conference call or presentation 26-Apr-19 11:00am GMT
Q1 2019 AstraZeneca PLC Earnings Call
- Benzinga•18 days ago
The Daily Biotech Pulse: FDA Nod For Sanofi's Dengue Vaccine, Veracyte Offering, Biogen Reports Positive Data
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 1) Alcon AG (NYSE: ALC ) (announced presentation of new ...
- Market Realist•18 days ago
AstraZeneca’s Lynparza Gives a Strong Performance in Q1
How AstraZeneca Is Looking after Its First-Quarter Results(Continued from Prior Part)Lynparza’s first-quarter performance In the first quarter, AstraZeneca’s (AZN) Lynparza sales rose 99% YoY (year-over-year) to $237 million on a reported
- Reuters•18 days ago
AstraZeneca ties up with France's Transgene to develop viral immunotherapies
Viral immunotherapy represents a new way of treating cancer by using transgenes, or genes that are artificially introduced into the genome of another organism. "AstraZeneca will select the transgenes to be encoded within the virus and will be responsible for further in-vivo pre-clinical development and, subject to option exercise, clinical development and commercialisation of these novel oncolytic immunotherapies," Transgene said. AstraZeneca has been moving deeper into cancer therapy market through wide-ranging deals, including those for immunotherapy and targeted therapy.
Market Realist•19 days agoAstraZeneca’s Imfinzi Maintains Strong Growth in Q1
How AstraZeneca Is Looking after Its First-Quarter Results(Continued from Prior Part)Imfinzi’s first-quarter performanceIn the first quarter, AstraZeneca’s (AZN) Imfinzi saw sales of $295 million, mainly driven by its rapid uptake as an
- Market Realist•19 days ago
AstraZeneca’s Tagrisso Sees the Fastest Growth in Q1
How AstraZeneca Is Looking after Its First-Quarter Results(Continued from Prior Part)Tagrisso’s first-quarter performanceIn the first quarter, AstraZeneca’s (AZN) Tagrisso sales rose 86% YoY (year-over-year) to $630 million on a reported basis
- TechCrunch•19 days ago
BenevolentAI starts AI collaboration with AstraZeneca to accelerate drug discovery
BenevolentAI is an AI company where AI actually means something. Founded in 2013, it focuses on "accelerating the journey from data to medicines." To achieve that, it has raised a whopping $202 million to look at early drug discovery through to late-stage clinical development, and has a research facility in Cambridge, U.K. where there is plenty of AI talent to be had. Today it has inked a long-term collaboration with pharma giant AstraZeneca to use AI and machine learning for the discovery and development of new treatments for chronic kidney disease (CKD) and idiopathic pulmonary fibrosis (IPF).
Market Realist•19 days agoAstraZeneca’s Expense Guidance for Fiscal 2019
How AstraZeneca Is Looking after Its First-Quarter Results(Continued from Prior Part)Expense guidanceIn its first-quarter press release, AstraZeneca (AZN) guided for its fiscal 2019 core operating expenses rising YoY (year-over-year) by a low
- Simply Wall St.•19 days ago
An Intrinsic Calculation For AstraZeneca PLC (LON:AZN) Suggests It's 46% Undervalued
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Does the May share price for AstraZeneca PLC (LON:AZN) reflect what it's really worth? Today, we will...
Market Realist•20 days agoWhat AstraZeneca Expects for EPS in Fiscal 2019
How AstraZeneca Is Looking after Its First-Quarter Results(Continued from Prior Part)EPS guidance In its first-quarter press release, AstraZeneca (AZN) reiterated its guidance for core EPS of $3.50–$3.70 in fiscal 2019. The company expects its YoY
Market Realist•20 days agoAstraZeneca Reiterates Its Fiscal 2019 Revenue Guidance
How AstraZeneca Is Looking after Its First-Quarter Results(Continued from Prior Part)Revenue guidanceIn its first-quarter press release, AstraZeneca (AZN) reiterated its guidance for high-single-digit percentage growth in its fiscal 2019 product
- Market Realist•20 days ago
What Analysts Recommend for AstraZeneca after Its Q1 Results
How AstraZeneca Is Looking after Its First-Quarter ResultsStock price movement On April 26, AstraZeneca (AZN) announced its first-quarter results. Its revenue rose 6% YoY (year-over-year) to $5.49 billion on a reported basis and 11% on a CER
- Kiplinger•20 days ago
Health Care Stocks: Buy Them While They're Down
Why this sector should outperform for years to come
- Zacks•20 days ago
AVEO Pharmaceuticals (AVEO) to Post Q1 Earnings: What's Up?
During AVEO Pharmaceuticals' (AVEO) Q1 conference call, investor focus will be on its NDA submission for Fotivda in the United States pertaining to the treatment of advanced or metastatic RCC.
